Vardenafil Hydrochloride

Vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. Vardenafil hydrochloride tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. ( 1 )

12.1 Mechanism of Action Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection.

With Mean elimination half-life of 7 to 11 hours across adult Vardenafil Hydrochloride dosing residence kinetics and Oral fraction absorbed ranges from 70% to 82% (Vardenafil Hydrochloride 5) bioavailability, Vardenafil Hydrochloride undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of vardenafil hydrochloride and establishes therapeutic activity over oral tmax achieved within 2 to 5 hours following vardenafil hydrochloride ingestion.

Standard adult regimens span 5 mg/1 Tablet, 10 mg/1 Tablet, 20 mg/1 Tablet, 5 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, Film Coated. Prescribers screen specifically against previous anaphylactoid or exfoliative reaction attributed to vardenafil hydrochloride; clinical scenarios where phosphodiesterase 5 inhibitor exposure from vardenafil hydrochloride poses unacceptable risk, while community micro-logs most frequently note nausea (12.1% of reports), headache (10.7% of reports), dizziness (6.4% of reports).